For type 2 diabetes, usually yes. Ozempic is approved to improve blood sugar in adults with type 2 diabetes, and to lower heart and kidney risks in adults with type 2 diabetes[1]. Novo Nordisk says Medicaid provides its own prescription coverage for Ozempic, with costs that vary[2]. Weight loss is where the answer turns on your state. The cash price, for comparison, is in Ozempic cost.
Why diabetes and weight loss get different answers
Under the Medicaid drug rebate program, states must cover nearly all approved drugs, but Congress exempted antiobesity medications[3]. The statute lists drugs, or uses of drugs, that a state may exclude or restrict, and the first item is “agents when used for anorexia, weight loss, or weight gain”[4].
That exclusion is about the use, not the molecule. Ozempic prescribed for type 2 diabetes is not a weight-loss use. Wegovy or Zepbound prescribed for weight is, so a state can leave it out.
A state can also put any covered drug behind prior authorization[4]. So even a covered Ozempic prescription may need your prescriber to document the diagnosis first.
How many states cover what
One study read the public preferred drug lists of 47 state Medicaid programs in the first quarter of 2023[3]. 39 states (83%) had unrestricted coverage of at least one of the two diabetes GLP-1 drugs it tracked, Victoza or Ozempic[3].
Only 10 of 47 (21%) covered at least one antiobesity medication[3]. The authors note that state lists may have changed since early 2023[3], so your state’s current preferred drug list is the answer that counts.
What changed in 2026: the BALANCE model
CMS’s BALANCE model negotiates GLP-1 prices and coverage terms with the makers on behalf of state Medicaid programs that choose to join[5]. Its drug list covers every form of Ozempic, Rybelsus, Wegovy and Mounjaro, the Zepbound KwikPen and Foundayo, for weight management as well as their existing uses[5].
May 2026
States can begin to join
Coverage for weight loss can start in Medicaid as early as this month.
Through January 2027
The joining window stays open
State Medicaid agencies can join up to January 1, 2027.
Every enrollee
A lifestyle program comes with it
Anyone getting a GLP-1 for weight under BALANCE in Medicaid gets a maker-provided lifestyle program at no cost.
Participation is voluntary for states and for makers[5]. CMS says coverage depends on who takes part, that patients face criteria including prior authorization, and that the model does not guarantee coverage for any individual[5]. Ask your state Medicaid agency or managed care plan whether it has joined.
Copay cards, free-drug programs and cash
People enrolled in Medicaid are not eligible for the Ozempic copay card, which lets commercially insured patients pay as little as $25[2]. They can use Novo Nordisk’s self-pay offer[2]: $199 a month for the first 2 fills at the lowest doses for new patients, then $349 through 1 mg and $499 at 2 mg[2]. A self-pay purchase cannot be sent to Medicaid for reimbursement[2].
Compounded semaglutide is outside Medicaid: it is not FDA approved and is sold for cash by telehealth sellers. Its monthly prices are on the semaglutide price board, and the price check tool tests a quote against them. The compounding guide explains why those products are not a copy of Ozempic.
For the same question on other payers, see does Medicare cover Ozempic and is Wegovy covered by insurance. The one thing to ask your plan: is the prescription coded for diabetes or for weight?